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TO THE EDITOR
Recent concern that vaccinia virus (VV)
might be used as a bioterror weapon
has led to contingency plans for mass
vaccination; however, a major concern
is that patients with atopic dermatitis
(AD) are susceptible to eczema vacci-
natum (EV), a complication of smallpox
vaccination (Copeman and Banatvala,
1971; Boguniewicz and Leung, 2010).
This has prompted the National Insti-
tutes of Health/National Institute of
Allergy and Infectious Diseases to form
the Atopic Dermatitis Vaccinia Net-
work for EV research. In affected
individuals, VV spreads through skin,
resulting in large primary lesions and
satellite lesions, and infects internal
organs. Vaccinia Ig (VIG) has been
used to prevent and treat EV in AD
patients accidentally exposed to, or
inoculated with, VV (Copeman and
Banatvala, 1971; Goldstein et al.,
1975). Studies in the literature reveal a
mean EV mortality rate of 4% in AD
patients treated with VIG, compared
with 5% and 40% in two studies of
historical controls (Hopkins and Lane,
2004). Four controlled studies and one
observational study reported promising
results with the use of VIG to prevent
smallpox in contacts of patients with
documented smallpox (Hopkins and
Lane, 2004). However, there have been
no controlled trials to establish the
efficacy of VIG in the prevention and
treatment of EV in AD patients.
We previously reported that BALB/c
mice inoculated with VV at sites of Th2-
biased allergic skin inflammation eli-
cited by epicutaneous (EC) ovalbumin
(OVA) sensitization exhibit features of
EV, including satellite lesions and VV
dissemination (Oyoshi et al., 2009). We
used this mouse model to examine the
efficacy of VIG in attenuating EV.
BALB/c mice were EC sensitized with
OVA or saline over 7 weeks (49 days),
then immediately inoculated with VV
Western Reserve strain (ATCC, VR-
1454) by skin scarification at the site
of EC sensitization using 107 PFU per
mouse, and euthanized 7 days later.
OVA-sensitized mice were divided into
four groups: three received a single
intraperitoneal injection of 10mg per
mouse of polyclonal anti-VV Ig (ATCC,
NR-2632) on day 1, þ 1, or þ3 of VV
inoculation; a fourth group received on
day 1 the same dose of control Ig
(CIG) prepared in-house from donors
never vaccinated with VV (Supplemen-
tary Figure S1 online). VV inoculation
of CIG-treated mice in OVA-sensitized
skin sites resulted in modest, but
significant, weight loss compared with
mice inoculated with VV at saline-
exposed sites. All three groups of
VIG-treated OVA-sensitized mice were
protected against weight loss (Supple-
mentary Figure S2 online). Mice injec-
ted with VIG at days 1 and þ1, but
not þ 3, developed significantly smal-
ler primary lesions and lower numbers
of satellite lesions compared with CIG-
treated mice (Figure 1a–c). Quantita-
tive PCR analysis of VV genomes
demonstrated that all three groups of
Abbreviations: AD, atopic dermatitis; CIG, control Ig; EC, epicutaneous; EV, eczema vaccinatum; MVA,
modified vaccinia virus Ankara; OVA, ovalbumin; VIG, vaccinia Ig; VV, vaccinia virus
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VIG-treated mice had significantly
decreased viral loads in inoculated skin
and internal organs compared with
CIG-treated controls (Figure 1d). The
reduction of satellite lesions in day þ
1-treated mice is consistent with a
previous study (Shearer et al., 2005).
The failure of day þ3 VIG administra-
tion to affect skin lesions despite
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Figure 1. Treatment with vaccinia Ig (VIG) decreases the size of primary lesions, the number of satellite lesions, and vaccinia virus (VV) dissemination
caused by VV inoculation at the sites of allergic skin inflammation. (a–c) Primary and satellite lesions in BALB/c mice inoculated with VV in saline
(Sal)- and ovalbumin (OVA)-sensitized skin (a), area of primary lesions (b), and number of satellite lesions (c) 7 days after VV inoculation. Mice were
treated with control Ig (CIG) or VIG on day 1, þ 1, or þ 3 of VV inoculation. Polyclonal antivaccinia virus (immune globulin G, human), NR-2632,
was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID. Dashed circles indicate primary lesions.
Arrows indicate satellite lesions. Lesion sizes were analyzed using the NIH image software Image J. (d) Viral load in skin and internal organs. Viral genomes were
quantified by real-time PCR as described previously (Oyoshi et al., 2009). Columns and error bars represent mean and SEM (n¼5 per group). One-way
analysis of variance was used to determine statistical differences between groups. *Po0.05, **Po0.01. EC, epicutaneous; NS, not significant.
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Figure 2. Cytokine expression and histology of vaccinia virus (VV)-inoculated skin of mice treated with vaccinia Ig (VIG). (a) Representative
hematoxylin and eosin-stained sections of VV inoculation sites. Bars¼ 100mm ( 200 magnification) or 25mm ( 1,600 magnification). Arrows indicate
neutrophils. (b) Epidermal thickness. (c) Cytokine mRNA expression as fold induction relative to VV-inoculated saline-exposed skin. Cytokine expression
in the skin was assessed by quantitative real-time PCR (Oyoshi et al., 2009). One-way analysis of variance was used to determine statistical differences
between groups. Columns and error bars represent mean and SEM (n¼ 5 per group). *Po0.05, **Po0.01. CIG, control Ig; EC, epicutaneous; NS, not significant;
OVA, ovalbumin; Sal, saline.
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drastically reducing viral load suggests
that delayed VIG treatment could have
allowed greater early viral replication
resulting in more robust cutaneous
inflammation.
VV-encoded epidermal growth fac-
tor and anti-apoptotic protein F1L
promote cell survival (Postigo et al.,
2009), and VV antigens colocalize with
proliferating keratinocytes (Fisher et al.,
2011). VV inoculation in OVA-sensi-
tized skin resulted in a significant
increase in epidermal thickness in
CIG-treated mice (Figure 2a and b).
This was inhibited by VIG treatment.
IFN-g inhibits (Combadiere et al.,
2004), whereas Th2 and Th17 cyto-
kines promote, VV replication in vivo
and in vitro (Howell et al., 2006;
Oyoshi et al., 2009). OVA-sensitized
skin of CIG-treated mice exhibited an
intense infiltrate with neutrophils, and
an increase in local mRNA expression
of Th2 cytokines (IL-4 and IL-13), IL-17,
with no significant change in IFN-g
(Figure 2c). Cellular infiltration at VV-
inoculated sites, which was predomi-
nantly neutrophilic, was decreased
more in mice treated with VIG at days
–1 and þ1, than day þ3 (Figure 2a
and b). All three groups of VIG-treated
mice showed decreased levels of Th2
cytokines in VV-inoculated skin com-
pared with CIG-treated mice, with no
change in IFN-g (Figure 2c). Mice
treated with VIG at days 1 and þ 1,
but not day þ3, exhibited significantly
decreased levels of IL-17 mRNA
expression in VV-inoculated skin
(Figure 2b). The failure of day þ3
VIG-treated mice to decrease IL-17
levels correlates with the persistence of
neutrophils and inflammatory lesions in
their skin, and is consistent with IL-17
being critical for neutrophil infiltration
in our EV model (Oyoshi et al., 2009).
Splenocytes from all three groups of
VIG-treated mice secreted significantly
less IL-4, IL-13, IFN-g, and IL-17 in
response to VV stimulation compared
with splenocytes from CIG-treated mice
(Po0.01, Supplementary Figure S3a
online). This is likely due to the
decreased antigenic stimulation in
VIG-treated mice. However, the pro-
tective VV-specific IgG2a antibody
response (Xu et al., 2004) was compar-
able in all groups, indicating that
VV-treated mice generated sufficient
T-helper-cell activity to drive normal
IgG2a production (Supplementary
Figure S3b online). In humans, VIG
prophylaxis does not interfere with
the vaccination reaction (Nanning,
1962).
Our results are in agreement with a
recent study that used neutralizing
human mAbs in VV-infected NC/Nga
mice (Tomimori et al., 2011). Several
mechanisms may account for the effi-
cacy of VIG in limiting viral spread.
Direct neutralization of the virus is
likely. The IgG Fc region in VV-VIG
antigen–antibody complexes and anti-
idiotypic–anti-VIG complexes might ac-
tivate FcgRþ effector cells (e.g., macro-
phages and NK cells) to limit VV
replication (Ballow, 2011). Further
studies are needed to understand the
precise mechanisms of action of VIG in
attenuating EV.
The dose of VIG we used is equiva-
lent to a dose of 500mg kg1 in hu-
mans, which is close to the
recommended dose for treatment of
EV (400mg kg1). Thus, our data sug-
gest that VIG may be effective in
preventing and treating EV. We recently
showed that attenuated VV strain–mo-
dified vaccinia virus Ankara (MVA)
protects mice inoculated with VV in
OVA-sensitized skin from VV infection
(Oyoshi et al., 2011). A dual strategy of
MVA immunization and VIG adminis-
tration should be evaluated in prevent-
ing EV in patients with AD.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by NIH grant
HHSN272201000020C.
Michiko K. Oyoshi1, Narayanaswamy
Ramesh1 and Raif S. Geha1
1Division of Immunology, Department of
Pediatrics, Children’s Hospital, Harvard
Medical School, Boston, Massachusetts, USA
E-mail: raif.geha@childrens.harvard.edu
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Ballow M (2011) The IgG molecule as a biological
immune response modifier: mechanisms of
action of intravenous immune serum globulin
in autoimmune and inflammatory disorders.
J Allergy Clin Immunol 127:315–23
Boguniewicz M, Leung DY (2010) Recent insights
into atopic dermatitis and implications for
management of infectious complications.
J Allergy Clin Immunol 125:4–13
Combadiere B, Boissonnas A, Carcelain G et al.
(2004) Distinct time effects of vaccination on
long-term proliferative and IFN-gamma-
producing T cell memory to smallpox in
humans. J Exp Med 199:1585–93
Copeman PW, Banatvala JE (1971) The skin and
vaccination against smallpox. Br J Dermatol
84:169–73
Fisher RW, Reed JL, Snoy PJ et al. (2011)
Postexposure prevention of progressive
vaccinia in SCID mice treated with vaccinia
immune globulin. Clin Vaccine Immunol
18:67–74
Goldstein JA, Neff JM, Lane JM et al. (1975)
Smallpox vaccination reactions, prophylaxis,
and therapy of complications. Pediatrics
55:342–7
Hopkins RJ, Lane JM (2004) Clinical efficacy of
intramuscular vaccinia immune globulin: a
literature review. Clin Infect Dis 39:819–26
Howell MD, Gallo RL, Boguniewicz M et al.
(2006) Cytokine milieu of atopic dermatitis
skin subverts the innate immune response to
vaccinia virus. Immunity 24:341–8
Nanning W (1962) Prophylactic effect of anti-
vaccinia gamma-globulin against post-vacc-
inal encephalitis. Bull World Health Organ
27:317–24
Oyoshi MK, Elkhal A, Kumar L et al. (2009)
Vaccinia virus inoculation in sites of
allergic skin inflammation elicits a vigorous
cutaneous IL-17 response. Proc Natl Acad Sci
USA 106:14954–9
Oyoshi MK, Wang JY, Geha RS (2011) Immuniza-
tion with modified vaccinia virus Ankara
prevents eczema vaccinatum in a murine
model of atopic dermatitis. J Allergy Clin
Immunol 128:890–2 e3
Postigo A, Martin MC, Dodding MP et al. (2009)
Vaccinia-induced epidermal growth factor
receptor-MEK signalling and the anti-apopto-
tic protein F1L synergize to suppress cell
death during infection. Cell Microbiol 11:
1208–18
Shearer JD, Siemann L, Gerkovich M et al. (2005)
Biological activity of an intravenous prepara-
tion of human vaccinia immune globulin in
mouse models of vaccinia virus infection.
Antimicrob Agents Chemother 49:2634–41
Tomimori Y, Kawakami Y, McCausland MM et al.
(2011) Protective murine and human mono-
clonal antibodies against eczema vaccina-
tum. Antivir Ther 16:67–75
Xu R, Johnson AJ, Liggitt D et al. (2004) Cellular
and humoral immunity against vaccinia virus
infection of mice. J Immunol 172:6265–71
www.jidonline.org 1301
MK Oyoshi et al.
Vaccinia Immune Globulin Prevents Eczema Vaccinatum
